Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
17 Apr 2018 07:00 AM
RNS
Topline results of Lupuzor Pivotal Phase III Trial
28 Mar 2018 07:00 AM
RNS
Appointment of Joint Broker
23 Mar 2018 07:00 AM
RNS
Lupuzor Pivotal Phase III Study Update
05 Mar 2018 04:13 PM
RNS
AIM Notice (17)
15 Feb 2018 07:00 AM
RNS
London Investor Evening
09 Feb 2018 02:00 PM
RNS
Holding(s) in Company
07 Feb 2018 09:35 AM
RNS
Holding(s) in Company
05 Feb 2018 07:00 AM
RNS
Holding(s) in Company
31 Jan 2018 10:23 AM
RNS
Holding(s) in Company
24 Jan 2018 07:00 AM
RNS
Successful Placing to Raise £10 Million
18 Jan 2018 07:00 AM
RNS
Completion of LupuzorT Pivotal Phase III Study
21 Dec 2017 07:05 AM
RNS
Grant of Options
21 Dec 2017 07:00 AM
RNS
Last patient completes dosing in LupuzorT Trial
28 Nov 2017 12:00 PM
RNS
Holding(s) in Company
24 Nov 2017 01:32 PM
RNS
Grant of Options
02 Nov 2017 07:00 AM
RNS
Update on LupuzorT Pivotal Phase III Study
16 Oct 2017 03:29 PM
RNS
Holding(s) in Company
04 Oct 2017 07:00 AM
RNS
Completion of Lanstead Sharing Agreement
27 Sep 2017 07:00 AM
RNS
Interim Results
26 Sep 2017 07:00 AM
RNS
Preparation of Lupuzor'sT Regulatory Submissions
21 Sep 2017 07:00 AM
RNS
Update on LupuzorT Pivotal Phase III Study
19 Sep 2017 07:00 AM
RNS
Notification of Interim Results
18 Aug 2017 05:09 PM
RNS
AIM Rule 17 Notice
12 Jul 2017 11:00 AM
RNS
Grant of Options
30 Jun 2017 12:04 PM
RNS
Result of AGM
30 Jun 2017 07:00 AM
RNS
Update on LupuzorT Pivotal Phase III Study
07 Jun 2017 07:00 AM
RNS
Annual Report & Notice of AGM
01 Jun 2017 07:00 AM
RNS
Final Results
22 May 2017 07:00 AM
RNS
Notification of Full Year Results
17 May 2017 07:00 AM
RNS
Update on Lupuzor Phase III Study
31 Mar 2017 10:17 AM
RNS
New Employee Share Option Plan & Grant of Options
31 Mar 2017 08:33 AM
RNS
New Employee Share Option Plan & Grant of Options
24 Mar 2017 07:00 AM
RNS
ImmuPharma to present at Master Investor Show
22 Mar 2017 08:51 AM
RNS
Holding(s) in Company
20 Mar 2017 11:41 AM
RNS
Holding(s) in Company
20 Mar 2017 07:00 AM
RNS
Holding(s) in Company
10 Mar 2017 03:52 PM
RNS
£4.1 Million Fund Raise via Accelerated Bookbuild
10 Mar 2017 07:00 AM
RNS
Accelerated Bookbuild for the Issue of Equity
06 Mar 2017 03:55 PM
RNS
Holding(s) in Company
17 Feb 2017 02:04 PM
RNS
Holding(s) in Company
25 Jan 2017 07:00 AM
RNS
Update on Lupuzor Phase III Study
24 Jan 2017 07:00 AM
RNS
Change of Adviser
29 Dec 2016 10:54 AM
RNS
Holding(s) in Company
22 Dec 2016 07:00 AM
RNS
Update on Lupuzor Pivotal Phase III Study
16 Nov 2016 07:00 AM
RNS
Update on Cancer Compound IPP-204106 'Nucant'
09 Nov 2016 07:00 AM
RNS
Holding(s) in Company
26 Oct 2016 03:42 PM
RNS
Holding(s) in Company
21 Oct 2016 05:13 PM
RNS
Close of Accelerated Bookbuild
21 Oct 2016 01:33 PM
RNS
Proposed Accelerated Bookbuild for Vendor Placing
30 Sep 2016 07:00 AM
RNS
Half-year Report

ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France. 

ImmuPharma listed on AIM under the ticker IMM. 

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

IMM share price listed in London at 1,190p in 2000. 

UK 100